Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BZH6

UPID:
WDR11_HUMAN

ALTERNATIVE NAMES:
Bromodomain and WD repeat-containing protein 2; WD repeat-containing protein 15

ALTERNATIVE UPACC:
Q9BZH6; Q5VWA1; Q9P2J6

BACKGROUND:
The WD repeat-containing protein 11, identified for its involvement in the Hedgehog (Hh) signaling pathway, is essential for ciliogenesis and influences the processing of GLI3. Its cooperation with EMX1 is crucial for the expression of downstream Hh pathway genes and the production of gonadotropin-releasing hormone.

THERAPEUTIC SIGNIFICANCE:
Associated with diseases such as Hypogonadotropic hypogonadism 14 with or without anosmia and Intellectual developmental disorder, autosomal recessive 78, the study of WD repeat-containing protein 11 offers a promising avenue for developing targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.